Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02962661 · ClinicalTrials.gov registry record · Phase 1

Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines

A Phase 1 study of Heart Failure and Malignant Solid Neoplasm, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
Phase 1
Development phase
72
Enrollment target
1
Study location

NCT02962661 is a Phase 1 study of Heart Failure and Malignant Solid Neoplasm that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 72 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02962661, a Phase 1 study of Heart Failure and Malignant Solid Neoplasm, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
Phase 1
Development phase
72 participants
Enrollment target
1
Study location

Study Summary

This randomized pilot phase I trial studies the side effects of donor bone marrow derived mesenchymal stem cells in controlling heart failure in patients with cardiomyopathy caused by anthracyclines. Donor bone marrow derived mesenchymal stem cells may help to control symptoms of heart failure and improve heart function.

Conditions Studied

Heart Failure Malignant Solid Neoplasm Hematopoietic and Lymphoid Cell Neoplasm Cardiomyopathy

Interventions

  • OTHER Laboratory Biomarker Analysis
  • OTHER Best Practice
  • DRUG Mesenchymal Stem Cell Transplantation

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 72 participants
Start Date 2020-07-18
Est. Completion 2026-07-30
Phase Phase 1

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02962661

The ClinicalTrials.gov registry entry for NCT02962661 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (96% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Heart Failure appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.

NCT02962661 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT02962661 about?

NCT02962661 is a clinical study titled "Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines". This randomized pilot phase I trial studies the side effects of donor bone marrow derived mesenchymal stem cells in controlling heart failure in patients with cardiomyopathy caused by anthracyclines. Donor bone marrow derived mesenchymal stem cells may help to control symptoms of heart failure and i...

What is the current status of trial NCT02962661?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2020-07-18. Estimated completion is 2026-07-30.

What conditions does trial NCT02962661 study?

This clinical trial studies the following conditions: Heart Failure, Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Cardiomyopathy.

What interventions are being tested in trial NCT02962661?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Best Practice (OTHER), Mesenchymal Stem Cell Transplantation (DRUG).

Who is sponsoring clinical trial NCT02962661?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02962661 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Heart Failure

All registered trials for this condition

Malignant Solid Neoplasm

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.